How Manufacturers Prepare for Notified Body Opinion in Europe?

Europe maintains strict regulatory control over drug device combination products. Manufacturers who plan market entry in the European Union face a detailed review process. One major step involves evaluation from a Notified Body. This process confirms device safety, performance, and regulatory compliance before market authorization.

Preparation plays a major role in approval success. Companies who plan early, organize technical documentation, and follow regulatory guidelines reduce delays during evaluation.

Understanding the Regulatory Requirement

Drug device combination products contain two components. A medicinal substance and a medical device work together in a single product. The European regulatory system evaluates both parts to protect patient safety.

Under the European Medical Device Regulation (EU MDR 2017/745), manufacturers must submit documentation when a device includes a medicinal substance. Authorities review how the device interacts with the drug and how the product performs during clinical use.

This evaluation leads to a formal regulatory assessment called a notified body opinion. The assessment confirms whether the device component meets EU safety and performance requirements.

Regulators analyze scientific evidence, manufacturing controls, and product risk management before giving approval.

Early Regulatory Strategy

Preparation begins during product development. Companies define the regulatory pathway at an early stage to avoid delays later.

Manufacturers review classification rules under EU MDR. They analyze how the medicinal substance affects device performance. This decision determines the level of documentation required.

A regulatory strategy normally includes:

• Product classification review
• Identification of applicable EU regulations
• Gap analysis of technical documentation
• Timeline planning for submission

Early planning allows companies to identify missing data before submission. This reduces the risk of regulatory rejection.

Building Strong Technical Documentation

Technical documentation forms the foundation of the evaluation process. Regulators review these documents in detail before providing their assessment.

Manufacturers prepare a complete technical file that includes:

• Device description and specifications
• Intended purpose and clinical use
• Risk management documentation
• Design verification and validation reports
• Manufacturing and quality control procedures

The technical file demonstrates how the product performs safely in real medical environments.

Clinical evidence also plays a key role. Companies must provide clinical evaluation reports supported by scientific literature or clinical studies.

Regulators expect evidence showing safety, effectiveness, and compatibility between drug and device components.

Risk Management and Safety Evaluation

Risk management remains a critical regulatory requirement under ISO 14971. Manufacturers identify hazards related to device use and evaluate risk control measures.

A complete risk management file includes:

• Hazard identification
• Risk estimation
• Risk control methods
• Residual risk evaluation

Manufacturers must show that risk remains acceptable compared with clinical benefits.

Regulators also assess drug-device interaction risks. For example, they evaluate whether the device delivers the drug correctly or affects drug stability.

This analysis helps regulators determine overall product safety.

Clinical Evidence and Performance Data

Clinical evidence supports the safety and performance of the product. Manufacturers collect clinical data from multiple sources.

Common data sources include:

• Clinical investigations
• Scientific literature
• Post-market data from similar products
• Performance testing results

Regulators examine whether clinical evidence supports the product’s intended use.

The evaluation also reviews patient safety, device functionality, and long-term performance.

Manufacturers must explain how the product benefits patients and how potential risks remain controlled.

Quality Management System Compliance

A certified quality management system strengthens regulatory submissions. Most manufacturers follow ISO 13485 standards to maintain consistent product quality.

The system covers areas such as:

• Design control
• Supplier management
• Manufacturing processes
• Product testing and validation
• Corrective and preventive actions

Regulators review quality management documentation to confirm manufacturing reliability.

A strong quality system demonstrates that the company controls production processes and maintains product consistency.

Regulatory Submission and Review Process

Once documentation is ready, manufacturers submit the regulatory file for review.

The evaluation process involves several steps.

Regulators review the technical documentation. They analyze risk management files and clinical evidence. They examine how the device interacts with the medicinal substance.

During review, regulators often send questions or requests for clarification.

Manufacturers respond with additional documentation or scientific justification. Clear and organized responses improve review efficiency.

At the end of the evaluation, regulators provide their conclusion through a notified body opinion.

This outcome supports further regulatory approval steps required for EU market access.

Common Challenges Manufacturers Face

Many companies encounter delays during regulatory evaluation. These delays usually occur due to incomplete documentation or unclear scientific evidence.

Common challenges include:

• Missing clinical evidence
• Weak risk management analysis
• Incomplete technical documentation
• Poor alignment with EU MDR requirements

Manufacturers who address these issues early improve their approval timeline.

Regulatory expertise also helps companies avoid costly submission errors.

Role of Expert Regulatory Support

Regulatory preparation requires specialized knowledge. Many companies partner with regulatory experts who understand EU MDR requirements and submission processes.

Professional regulatory teams help manufacturers:

• Review product classification
• Build strong technical documentation
• Prepare risk management files
• Support regulatory submissions

Experienced consultants guide companies through the complex regulatory framework.

Companies such as 3iconcept Medical Device Solutions support manufacturers with regulatory planning, documentation development, and EU compliance strategies for combination products.

Expert guidance helps companies improve submission quality and avoid regulatory delays.

Final Thoughts

European regulatory approval demands careful preparation. Drug device combination products undergo strict evaluation before reaching patients.

Manufacturers who prepare strong documentation, follow EU MDR requirements, and provide clinical evidence improve approval success.

Regulatory planning, risk management, and quality systems form the foundation of a successful submission.

Companies who start preparation early and follow structured regulatory strategies move through the approval process with greater efficiency and confidence.